Malaysian Society for Quality in Health (MSQH) Earns Global Recognition for its Organisational and Surveyor Training Programme Accreditation

Malaysian Society for Quality in Health (MSQH) Earns Global Recognition for its Organisational and Surveyor Training Programme Accreditation

KUALA LUMPUR, Malaysia, Jan. 14, 2025 /PRNewswire/ -- The Malaysian Society for Quality in Health (MSQH), a leading national healthcare accreditation body dedicated to ensuring the highest standards of quality and safety in healthcare services,...

CARsgen's Allogeneic CD19/CD20 CAR-T Therapy Administers First Dose in an Investigator-Initiated Trial

CARsgen's Allogeneic CD19/CD20 CAR-T Therapy Administers First Dose in an Investigator-Initiated Trial

SHANGHAI, Jan. 13, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that KJ-C2219, an...

Nature's Miracle Holding, Inc. Announces Up to $29.7 Million Financing

Nature's Miracle Holding, Inc. Announces Up to $29.7 Million Financing

ONTARIO, Calif., Jan. 13, 2025 /PRNewswire/ -- Nature's Miracle Holding, Inc. (Nasdaq: NMHI) ("Nature's Miracle"), a growing agriculture technology company providing equipment and services to growers, announced that it entered into a Securities...

CBC Group's R-Bridge Announces US$40M Synthetic Royalty-Backed Financing for Mirxes to Advance Global Expansion

CBC Group's R-Bridge Announces US$40M Synthetic Royalty-Backed Financing for Mirxes to Advance Global Expansion

- R-Bridge will provide bespoke financing of US$40 million with a synthetic royalty structure and flexible repayment terms - Financing will accelerate Mirxes, Singapore-based miRNA tech company's innovation and commercialization of cancer early...

Scintimun® Commercialization Partnership with Curium Pharma

Scintimun® Commercialization Partnership with Curium Pharma

MELBOURNE, Australia and LIÈGE, Belgium, Jan. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has entered into an agreement with Curium Pharma for the transfer of marketing...

HARD ROCK HOTEL PENANG MARKS 10 YEARS OF COMMUNITY SPIRIT WITH ROCK TO ROCK RUN 2025

HARD ROCK HOTEL PENANG MARKS 10 YEARS OF COMMUNITY SPIRIT WITH ROCK TO ROCK RUN 2025

GEORGE TOWN, Malaysia, Jan. 13, 2025 /PRNewswire/ -- Hard Rock Hotel Penang proudly announces the return of its highly anticipated charity event, Rock to Rock Run, scheduled for 15 June 2025 at 6.00 am. Press Conference of Rock to Rock Run 2025 at...

Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform

Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform

MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has entered into an asset purchase agreement with antibody engineering company...

iM Global Partner mourns the passing of Philippe Uzan

iM Global Partner mourns the passing of Philippe Uzan

PARIS, Jan. 13, 2025 /PRNewswire/ -- It is with deep sadness that iM Global Partner (iMGP) announces the passing, one month ago, of our dear friend and colleague, Philippe Uzan. iM Global Partner mourns the passing of Philippe Uzan Philippe's...

Dunxin Financial Holdings Limited Announces Name Change to Eason Technology Limited

Dunxin Financial Holdings Limited Announces Name Change to Eason Technology Limited

HONG KONG, Jan. 11, 2025 /PRNewswire/ -- Dunxin Financial Holdings ("DXF" or the "Company") (OTC Pink: DXFFY, DXFFD) is pleased to announce that effective on January 10, 2025, the Company will change its name to "Eason Technology Limited" and its...

Harbour BioMed Announces License Agreement with Windward Bio for HBM9378/SKB378, an Anti-TSLP Fully Human Antibody for Immunological Diseases

Harbour BioMed Announces License Agreement with Windward Bio for HBM9378/SKB378, an Anti-TSLP Fully Human Antibody for Immunological Diseases

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 10, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody...

  • 1
  • ...
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • ...
  • 74
  • menu
    menu